Try our Advanced Search for more refined results

Expert Analysis

Precedex Decision Will Impact FDA's Use Code System

Law360, New York ( September 5, 2014, 10:58 AM EDT) -- The U.S. Food and Drug Administration's Aug. 18, 2014, decision[1] to accept Section VIII certifications for generic versions of Precedex, despite overlap between the labeled uses for these generic versions and the patent use code assigned to Precedex, has significant implications for generic and brand drug manufacturers and calls into question the FDA's administration of patent safeguards under the Hatch Waxman Act.[2]...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!